➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Express Scripts
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,092,541


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,092,541 protect, and when does it expire?

Patent 10,092,541 protects OTEZLA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,092,541
Title:Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
Abstract: Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.
Inventor(s): Day; Robert (Newtown, PA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:14/826,027
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,092,541
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 10,092,541

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE ⤷  Try it Free
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE ⤷  Try it Free
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE ⤷  Try it Free
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,092,541

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3188745 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 2016025686 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Baxter
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.